James L. Foght
Jump to navigation Jump to search
In 2005 he joined the board of directors of the Immune Response Corporation.
- "His scientific background along with his financial expertise will be an important addition to our board as we advance the clinical programs of IRC's two lead immune-based therapies: NeuroVax(TM) for multiple sclerosis (MS) and IR103 for HIV/AIDS," said Dr. Joseph O'Neill, President and Chief Executive Officer of The Immune Response Corporation.
- "Dr. Foght was formerly a Managing Director in the Investment Banking division of Prudential Vector Healthcare Group, a unit of Prudential Securities Incorporated. He joined Prudential in July 1999 with the acquisition of Vector Securities International, Inc., which he co-founded in 1988.
- "Previously, Dr. Foght was Senior Vice President and Co-head of Kidder Peabody's Life Sciences/Medical Products Specialty Group. Prior to that, Dr. Foght spent 23 years with E.I. du Pont de Nemours & Co., spending half of his career in research and research management. He became Managing Director of du Pont U.K. in 1979, with responsibility for 4,000 employees and revenues of $700 million annually. In 1981, Dr. Foght was responsible for the planning and implementation of a de novo pharmaceutical business for du Pont in Europe, Africa, and the Middle East. His responsibilities included managing clinical research, regulatory affairs, licensing, manufacturing, and sales and distribution from headquarters in Frankfurt, Germany. Later, Dr. Foght established a worldwide Technology Evaluation and Acquisition Group for du Pont in the life sciences area."